TITLE

Sirius Genomics Launches International Sepsis Study

PUB. DATE
November 2011
SOURCE
Worldwide Biotech;Nov2011, Vol. 23 Issue 11, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on an international sepsis study launched by biotechnology company Sirius Genomics. The stated goal of the study is to find a genetic biomarker for positive response to treatment with activated protein C. Activated protein C offers significant benefit for critical care physicians treating severe sepsis, as well as for patients. A brief information about Sirius Genomics is presented.
ACCESSION #
67094672

 

Related Articles

  • Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. Mina Hur; Hanah Kim; Seungho Lee; Cristofano, Flavia; Magrini, Laura; Marino, Rossella; Gori, Chiara Serena; Bongiovanni, Cristina; Zancla, Benedetta; Cardelli, Patrizia; Di Somma, Salvatore // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background We investigated the diagnostic and prognostic utilities of procalcitonin (PCT), B-type natriuretic peptide (BNP), and neutrophil gelatinase-associated lipocalin (NGAL) in critically ill patients with suspected sepsis, for whom sepsis was diagnosed clinically or based on PCT...

  • The pediatric sepsis biomarker risk model. Wong, Hector R; Salisbury, Shelia; Qinag Xiao; Cvijanovich, Natalie Z; Hall, Mark; Allen, Geoffrey L; Thomas, Neal J; Freishtat, Robert J; Anas, Nick; Meyer, Keith; Checchia, Paul A; Lin, Richard; Shanley, Thomas P; Bigham, Michael T; Sen, Anita; Nowak, Jeffrey; Quasney, Michael; Henricksen, Jared W; Chopra, Arun; Banschbach, Sharon // Critical Care;2012, Vol. 16 Issue 5, p11652 

    Introduction: The intrinsic heterogeneity of clinical septic shock is a major challenge. For clinical trials, individual patient management, and quality improvement efforts, it is unclear which patients are least likely to survive and thus benefit from alternative treatment approaches. A robust...

  • The Procalcitonin And Survival Study (PASS) -- A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. Jensen, Jens-Ulrik; Lundgren, Bettina; Hein, Lars; Mohr, Thomas; Petersen, Pernille L.; Andersen, Lasse H.; Lauritsen, Anne Ø; Hougaard, Sine; Mantoni, Teit; Bømler, Bonnie; Thornberg, Klaus J.; Thormar, Katrin; Løken, Jesper; Steensen, Morten; Carl, Peder; Petersen, J. Asger; Tousi, Hamid; Søe-Jensen, Peter; Bestle, Morten; Hestad, Søren // BMC Infectious Diseases;2008, Vol. 8 Issue 1, Special section p1 

    Background: Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often difficult to assess because symptoms cannot be...

  • Agreements/contracts.  // Medical Device Daily;11/6/2009, Vol. 13 Issue 215, p3 

    The article reports that pharmacogenomic diagnostics provider Sirius Genomics in Vancouver, British Columbia, has signed its first contribution with the National Research Council of Canada Industrial Research Assistance Program. The research funding will be used for the study of genomic...

  • Prokalzitoninbasierte Algorithmen. Hochreiter, M.; Schroeder, S. // Anaesthesist;Jul2011, Vol. 60 Issue 7, p661 

    Sepsis is one of the most cost-intensive conditions of critically ill patients in intensive care medicine. Furthermore, sepsis is known to be the leading cause of morbidity and of mortality in intensive care patients. Early initiation of antibiotic therapy can significantly reduce mortality. The...

  • Oral Presentations 292-312.  // Intensive Care Medicine;Jan2004 Supplement 1, Vol. 30, pS78 

    Presents abstracts on intensive care medicine, presented at the 17th Annual Congress of the European Society of Intensive Care Medicine. "Differences of Heart Rate Variability Time Kinetics in Survivors and Non-Survivors of MODS," by H. Schmidt, P. Tymiec, D. Hoyer, U. Müller-Werdan and K....

  • Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Backes, Yara; Sluijs, Koenraad; Mackie, David; Tacke, Frank; Koch, Alexander; Tenhunen, Jyrki; Schultz, Marcus // Intensive Care Medicine;Sep2012, Vol. 38 Issue 9, p1418 

    Purpose: Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR) positively correlate with the activation level of the immune system. We reviewed the usefulness of systemic levels of suPAR in the care of critically ill patients with sepsis, SIRS, and bacteremia, focusing...

  • Inflammation-Controlling Sepsis Treatment Results in Improved Patient Outcomes. Dziedzic, Jessica // Pulmonary Reviews;Oct2007, Vol. 12 Issue 10, p35 

    The article discusses research being done on the influence of early hemodynamic optimization and biomarker patterns of severe sepsis and septic shock. It references a study by Emanuel P. Rivers and colleagues published in the September 2007 issue of "Critical Care Medicine." The study suggests...

  • Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Llewelyn, Martin J.; Berger, Mario; Gregory, Mark; Ramaiah, Ravi; Taylor, Amanda L.; Curdt, Ingo; Lajaunias, Frédéric; Graf, Rolf; Blincko, Stuart J.; Drage, Stephen; Cohen, Jonathan // Critical Care;2013, Vol. 17 Issue 2, Special section p2 

    Introduction: Although many sepsis biomarkers have shown promise in selected patient groups, only C-reactive protein and procalcitonin (PCT) have entered clinical practice. The aim of this study was to evaluate three promising novel sepsis biomarkers in unselected patients at admission to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics